Entrada Therapeutics, Inc. (TRDA)Healthcare | Biotechnology | Boston, United States | NasdaqGM
6.60 USD
-0.32
(-4.624%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5 a.m. EDT
Entrada Therapeutics presents a catastrophic long-term investment case driven by a collapsing business model and deteriorating fundamentals. The company is in a severe multi-year decline, having lost nearly 44% of its value over the last three years, with the most recent annual performance showing a staggering -62% drop. This is compounded by a massive -95.7% contraction in revenue and negative operating margins of -48%, indicating the core business is failing to generate income. While the balance sheet currently holds significant cash relative to debt, the relentless burn rate and shrinking top line suggest this liquidity is merely delaying inevitable insolvency rather than funding a turnaround. The recent news of a lawsuit and missed estimates further erodes any remaining credibility. Short-term, the stock remains trapped in a downtrend, trading well below its moving averages with no catalyst visible to reverse the slide. The lack of analyst coverage and the absence of any institutional options flow confirm that smart money has abandoned this vehicle. |
| Model | MAE |
|---|---|
| MSTL_69_84 ✓ | 0.514439 |
| AutoTheta | 0.521029 |
| AutoETS | 0.526300 |
| AutoARIMA | 0.526302 |
| MSTL_69 | 0.527832 |
| MSTL_84 | 0.530802 |
| MSTL | 0.532730 |
Forecast horizon: 60 days | Selected: MSTL_69_84
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 6.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.005 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.368 |
| Revenue per Share | 0.138 |
| Market Cap | 256,216,064 |
| Forward P/E | -2.03 |
| Beta | -0.26 |
| Website | https://www.entradatx.com |
As of July 11, 2026, 5 a.m. EDT: Options activity shows negligible volume and open interest across all expirations. There is no meaningful positioning in either calls or puts to indicate a specific speculative bias. Implied volatility is extremely low, suggesting a lack of active hedging or directional bets by market participants.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.017647028 |
| Address1 | One Design Center Place |
| Address2 | Suite 17- 500 |
| All Time High | 36.85 |
| All Time Low | 4.93 |
| Ask | 8.4 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 480,310 |
| Average Daily Volume3 Month | 420,226 |
| Average Volume | 420,226 |
| Average Volume10Days | 480,310 |
| Beta | -0.264 |
| Bid | 4.86 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 7.517 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.6 |
| Current Ratio | 13.903 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.87 |
| Day Low | 6.51 |
| Debt To Equity | 18.368 |
| Display Name | Entrada Therapeutics |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | -172,556,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.19 |
| Enterprise To Revenue | 5.701 |
| Enterprise Value | 32,712,416 |
| Eps Current Year | -3.79429 |
| Eps Forward | -3.25667 |
| Eps Trailing Twelve Months | -4.0 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.7977 |
| Fifty Day Average Change | -1.1977 |
| Fifty Day Average Change Percent | -0.15359658 |
| Fifty Two Week Change Percent | 1.7647028 |
| Fifty Two Week High | 16.45 |
| Fifty Two Week High Change | -9.85 |
| Fifty Two Week High Change Percent | -0.5987842 |
| Fifty Two Week Low | 4.93 |
| Fifty Two Week Low Change | 1.6700001 |
| Fifty Two Week Low Change Percent | 0.33874243 |
| Fifty Two Week Range | 4.93 - 16.45 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,635,514,200,000 |
| Float Shares | 19,495,591 |
| Forward Eps | -3.25667 |
| Forward P E | -2.02661 |
| Free Cashflow | -75,381,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 152 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -135,811,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.123100005 |
| Held Percent Institutions | 0.78802 |
| Implied Shares Outstanding | 38,820,616 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. |
| Long Name | Entrada Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 256,216,064 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_595472652 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -166,118,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 268,638,662 |
| Number Of Analyst Opinions | 4 |
| Open | 6.85 |
| Operating Cashflow | -131,700,000 |
| Operating Margins | -48.34629 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 857 520 9158 |
| Previous Close | 6.92 |
| Price Eps Current Year | -1.7394558 |
| Price Hint | 2 |
| Price To Book | 0.8780098 |
| Price To Sales Trailing12 Months | 44.652504 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.397 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.32 |
| Regular Market Change Percent | -4.62428 |
| Regular Market Day High | 6.87 |
| Regular Market Day Low | 6.51 |
| Regular Market Day Range | 6.51 - 6.87 |
| Regular Market Open | 6.85 |
| Regular Market Previous Close | 6.92 |
| Regular Market Price | 6.6 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 280,582 |
| Return On Assets | -0.26841998 |
| Return On Equity | -0.48282 |
| Revenue Growth | -0.957 |
| Revenue Per Share | 0.138 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 38,820,616 |
| Shares Percent Shares Out | 0.0544 |
| Shares Short | 2,111,685 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,727,002 |
| Short Name | Entrada Therapeutics, Inc. |
| Short Percent Of Float | 0.0845 |
| Short Ratio | 7.04 |
| Source Interval | 15 |
| State | MA |
| Symbol | TRDA |
| Target High Price | 25.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 18.75 |
| Target Median Price | 20.0 |
| Total Cash | 254,859,008 |
| Total Cash Per Share | 7.073 |
| Total Debt | 49,750,000 |
| Total Revenue | 5,738,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.591575 |
| Two Hundred Day Average Change | -2.9915748 |
| Two Hundred Day Average Change Percent | -0.31189612 |
| Type Disp | Equity |
| Volume | 280,582 |
| Website | https://www.entradatx.com |
| Zip | 2,210 |